• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What Would You Change About the EOM?


Constructive advice on improving the Enhancing Oncology Model (EOM) from our expert panel.

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, invites the panelists to discuss one element of the Enhancing Oncology Model (EOM) they would change, and why. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and COA president, called for CMS to include a factor to recognize the effects of COVID long haulers on total cost of care. Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, returned to the MEOS payments and suggested either making them higher or creating an add-on payment to reward data collection. And Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, agreed with higher MEOS payments to attract new participants but also called for a system that doesn't punish practices that prescribe newly approved, high cost drugs if they are right for the patient.

Related Videos
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Video 10 - "Bronchiectasis Exacerbation Management"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"
Related Content
© 2024 MJH Life Sciences
All rights reserved.